A multicenter comparison of MOG-IgG cell-based assays

Patrick J. Waters, PhD,* Lars Komorowski, PhD,* Mark Woodhall, PhD,* Sabine Lederer, PhD, Masoud Majed, MD, Jim Fryer, MS, John Mills, PhD, Eoin P. Flanagan, MB, BCH, Sarosh R. Irani, DPhil, MRCP, Amy C. Kunchok, MB, Andrew McKeon, MD, and Sean J. Pittock, MD

Neurology® 2019;92:e1250-e1255. doi:10.1212/WNL.0000000000007096

Abstract

Objectives
To compares 3 different myelin oligodendrocyte glycoprotein–immunoglobulin G (IgG) cell-based assays (CBAs) from 3 international centers.

Methods
Serum samples from 394 patients were as follows: acute disseminated encephalomyelitis (28), seronegative neuromyelitis optica (27), optic neuritis (21 single, 2 relapsing), and longitudinally extensive (10 single, 3 recurrent). The control samples were from patients with multiple sclerosis (244), hypergammaglobulinemia (42), and other (17). Seropositivity was determined by visual observation on a fluorescence microscope (Euroimmun fixed CBA, Oxford live cell CBA) or flow cytometry (Mayo live cell fluorescence-activated cell sorting assay).

Results
Of 25 samples positive by any methodology, 21 were concordant on all 3 assays, 2 were positive at Oxford and Euroimmun, and 2 were positive only at Oxford. Euroimmun, Mayo, and Oxford results were as follows: clinical specificity 98.1%, 99.6%, and 100%; positive predictive values (PPVs) 82.1%, 95.5%, and 100%; and negative predictive values 79.0%, 78.8%, and 79.8%. Of 5 false-positives, 1 was positive at both Euroimmun and Mayo and 4 were positive at Euroimmun alone.

Conclusions
Overall, a high degree of agreement was observed across 3 different MOG-IgG CBAs. Both live-cell-based methodologies had superior PPVs to the fixed cell assays, indicating that positive results in these assays are more reliable indicators of MOG autoimmune spectrum disorders.

*These authors contributed equally to this work.

From the Oxford Autoimmune Neurology Group (P.J.W., M.W., S.R.I.), Nuffield Department of Clinical Neurosciences, UK; Institute for Experimental Immunology (L.K., S.L.), Affiliated to Euroimmun AG, Luebeck, Germany, and Departments of Neurology (M.M., E.P.F., A.C.K., A.M., S.J.P.) and Laboratory Medicine and Pathology (J.F., J.M., E.P.F., A.C.K., A.M., S.J.P.), Mayo Clinic, College of Medicine, Rochester, MN.

Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

The Article Processing Charge was funded by Wellcome Trust.

This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Glossary

ADEM = acute disseminated encephalomyelitis; AQP4 = aquaporin-4; CBA = cell-based assay; DMA = disease-modifying agent; IDD = inflammatory demyelinating disorder; IgG = immunoglobulin G; IIF = indirect immunofluorescence; MOG = myelin oligodendrocyte glycoprotein; MS = multiple sclerosis; NMO = neuromyelitis optica; PPV = positive predictive value.

There is accumulating evidence that CNS inflammatory demyelinating disorders (IDDs), including forms of neuromyelitis optica (NMO) spectrum disorders, acute disseminated encephalomyelitis (ADEM), optic neuritis (recurrent more than single episode), and transverse myelitis are commonly associated with immunoglobulin G (IgG) targeting aquaporin-4 (AQP4) or myelin oligodendrocyte glycoprotein (MOG).\(^1\) Until their relatively recent discovery, patients with these disorders were commonly misdiagnosed as having multiple sclerosis (MS), yet contemporary findings show that MS, MOG-IgG, and AQP4-IgG–associated IDDIs have clinical, radiologic, pathologic, and prognostic differences.\(^5\)–\(^6\)

MOG-IgG–associated IDDs may have a higher prevalence in children and are often relapsing, commonly manifesting as optic neuritis. Attacks may be associated with accumulating neuronal injury and functional impairment. MOG-IgG may be transient or persistent, and its role as a predictor of relapse remains a focus of ongoing study. While MOG antibody has had a checkered past as a biomarker because of a lack of any specific disease association, contemporary methodologies using cell-based assays (CBAs) now define an autoimmune oligodendroglyopathy with a preferential response to immunosuppressants rather than disease-modifying agents (DMA) commonly used in MS.\(^5\)–\(^8\)

Early initiation and prolonged administration of such drugs may prevent relapses and reduce disability accrual, although randomized clinical trials have not yet been undertaken. MOG-IgG also provides important prognostic information. Hence, accurate serologic diagnosis is imperative to optimize clinical care.

A recent review article published in 2017 by key opinion leaders in the field stated that “methods for detecting MOG antibodies have improved substantially, with cell based assays (CBAs) being state of the art.”\(^1\) In this blinded study, 3 different MOG-IgG CBAs from 3 international centers were compared.

Methods

Standard protocol approvals, registrations, and patient consents

All patients in our study consented to the use of their medical records for research purposes. The study was approved by the Institutional Review Board of Mayo Clinic, Rochester, MN (No. 08-007846).

Serum samples from 394 patients and controls were tested: 91 patients were classified as having a MOG-IgG–like clinical phenotype and included ADEM (28), AQP4-IgG seronegative NMO (27, fulfilling Wingerchuk diagnostic criteria for NMO, either 1999 or 2006 [excluding antibody status]), optic neuritis (21 single, 2 relapsing), or longitudinally extensive transverse myelitis (10 single, 3 recurrent). The control samples were collected from patients with MS (244, selected from the Olmsted County MS population-based cohort), hypergammaglobulinemia (42), and other (17, encephalitis, glioma, Creutzfeldt-Jakob disease, glaucoma). Sensitivity was calculated as the percentage of positives cases within the MOG-IgG–like clinical phenotype cohort. Specificity was calculated as the percentage of positive cases in the MS cohort and those with other neurologic presentations inconsistent with an MOG-related clinical phenotype. Positive predictive value (PPV) was calculated as the percentage of positive test results in patients with MOG-IgG–like clinical phenotypes of all positive test results and estimates the reliability of a positive test result. In contrast, the negative predictive value is the percentage of negative test results in patients without an MOG-IgG–like clinical phenotype of all negative test results and is an estimate of how reliably a negative test result rules out the disease. This study was approved by the Mayo Clinic Institutional Review Board.

All samples were stored at −80°C at the Mayo Clinic central laboratory. They were divided into aliquots and provided frozen as coded samples to the 3 neuroimmunology laboratories: Mayo Clinic; Oxford, UK; and Euroimmun, Germany. All samples were tested by investigators blinded to the clinical information. Methodologies of the 3 assays are shown in table 1, and staining of cells considered positive and negative by all 3 assays is illustrated in the figure.

Data availability statement

The dataset used and analyzed during the current study is available from the corresponding author on reasonable request.

Results

Of the 25 case samples positive by any methodology, 21 were concordant on all 3 assays, 2 were positive by the Oxford assay and Euroimmun assay, and 2 were positive only by the Oxford assay.

Clinical specificity, as measured using a cohort of 244 patients with MS and 17 patients with disorders clearly outside of the autoimmune MOG spectrum, was 98.1% for Euroimmun, 99.6% for Mayo, and 100% for Oxford. The corresponding PPVs were 82.1%, 95.5%, and 100%, respectively. Negative predictive values were 79.0%, 78.8%, and 79.8%. Of the 5 false-positive findings in this cohort, 1 was positive by both
the Euroimmun and Mayo assays (table 2). The additional 4 false-positive results were limited to the Euroimmun CBA. Analytical specificity was high for all 3 assays; no false-positives were identified in a cohort of 42 patients with hypergammaglobulinemia. The results of this multicenter method comparison study of MOG-IgG testing are summarized in table 2. All pairwise comparisons revealed good interassay reliability with \( \kappa \) values >0.8 indicating a high degree of agreement across methods (Cohen \( \kappa \) statistic). Therefore, despite different methodologies and testing locations, the majority of samples achieved the same results across platforms. This is critical for the initial deployment of MOG-IgG–based assays because it provides confidence in the reliability of a positive result but also indicates that detection of MOG-IgG antibodies is robust and that these assays are inherently well standardized.

**Discussion**

Both live cell–based methodologies, distinct assays performed at different centers, had superior PPVs to the fixed assays, indicating that positive results in these assays are more reliable indicators of MOG spectrum disorders. ELISA is not a reliable methodology for MOG-IgG detection. MOG-IgG–related diseases may benefit from early and ongoing immunotherapies. Often, inflammatory idiopathic CNS disease such as ADEM, optic neuritis, and transverse myelitis are treated similarly to those with glial antibodies in the acute setting (steroids or plasmapheresis). However, for maintenance immunotherapy, patients without a glial antibody may be less likely to be treated with longer-term immunosuppressants, and longer treatment regimens are associated with fewer relapses in MOG-IgG–related diseases. A false-negative result would often result in a misdiagnosis of MS and consequent treatment with DMAs, which have been reported to worsen AQP4-IgG–positive IDDs, although some are effective for both disorders (anti-CD20 treatments). Data on DMAs exacerbating MOG-IgG disease are currently lacking.

Another concerning consequence of diagnostic inaccuracies is the detection of a false-positive result. Because MOG-IgGs will likely be commonly ordered in the clinical evaluation of a suspected demyelinating event, a false-positive result in a patient with a clinical diagnosis of MS might result in the selection of an immunosuppressant drug (e.g., mycophenolate mofetil, cellcept) rather than a Food and Drug Administration–approved DMA. In this study, 5 of 27 (18.5%) positive results in the commercial test were in control samples, giving a relatively poor PPV (82.1% vs 95.5%–100%). The test is simpler to run in routine diagnostic laboratories, but...
it has to be fixed to allow transport and storage. The fixation may generate cryptic epitopes, which could explain the clearly positive binding. These discrepancies have also been described in AQP4 assay comparisons. Future studies should address this issue in their design, which may help with a better understanding of this kind of discrepancy.

**Study funding**
Funding provided by the Center for MS and Autoimmune Neurology and Department Laboratory Medicine and Pathology, Mayo Clinic.

**Disclosure**
P. Waters and the University of Oxford hold patents and receive royalties and revenue for performing antibody assays in neurologic diseases. L. Komorowski is an employee of Euroimmun AG, a company that develops, produces, and manufactures immunoassays for the detection of disease-associated antibodies. M. Woodhall reports no disclosures relevant to the manuscript. S. Lederer is an employee of Euroimmun AG, a company that develops, produces, and manufactures immunoassays for the detection of disease-associated antibodies. M. Majed, J. Fryer, and J. Mills report no disclosures relevant to the manuscript. E. Flanagan receives research support as a site principal investigator for Medimmune on a study of MEDI551 in NMO spectrum disorders. S. Irani and the University of Oxford hold patents and receive royalties and revenue for performing antibody assays in neurologic diseases. A. Kunchok reports no disclosures relevant to the manuscript. A. McKeon has a patent pending for MAP1B antibody as a marker of...
Table 2  Distribution of MOG-IgG result by 3 assays in serum samples of cases and controls

|                        | Oxford      | Mayo        | Euroimmun   |
|------------------------|-------------|-------------|-------------|
| Sensitivity (95% CI)   | 27.5 (18.6–37.8) | 23.1 (14.9–33.1) | 25.3 (16.8–35.5) |
| Specificity (95% CI)   | 100 (98.6–100)   | 99.6 (97.9–100)   | 98.1 (95.6–99.4)   |
| PPV (95% CI)           | 100          | 95.5 (74.1–99.4) | 82.1 (64.2–92.2)  |
| NPV (95% CI)           | 79.8 (77.7–81.8) | 78.8 (76.8–80.6) | 79.0 (76.9–80.9)  |

IDDs considered within the autoimmune MOG spectrum, n (%)

|                        | Oxford | Mayo | Euroimmun |
|------------------------|--------|------|-----------|
| Total (91)             | 25 (27) | 21 (23) | 23 (25)   |
| ADEM (28)              | 7 (25)  | 6 (21)  | 7 (25)    |
| AQP4 seronegative NMO (27) | 16 (59) | 13 (48) | 14 (52)   |
| ON (23)                |        |       |           |
| Single (21)            | 0      | 0     | 0         |
| Relapsing (2)          | 1 (50) | 1 (50) | 1 (50)    |
| LETM (13)              |        |       |           |
| Single (10)            | 1 (10) | 1 (10) | 1 (10)    |
| Relapsing (3)          | 0      | 0     | 0         |

IDDs not considered within the autoimmune MOG spectrum

|                        | Oxford | Mayo | Euroimmun |
|------------------------|--------|------|-----------|
| MS (244)               | 0      | 1 (0.4%) | 5 (2%) |
| RRMS (157)             | 0      | 1 (0.6%) | 2 (1.2%) |
| SPMS (54)              | 0      | 0     | 2 (3.7%) |
| PPMS (15)              | 0      | 0     | 1 (6.7%) |
| CIS/RIS (18)           | 0      | 0     | 0         |

Other disorders

|                        | Oxford | Mayo | Euroimmun |
|------------------------|--------|------|-----------|
| Other (17)             | 0      | 0    | 0         |
| Encephalopathy (14)    | 0      | 0    | 0         |
| Glioma (2)             | 0      | 0    | 0         |
| Glaucoma (1)           | 0      | 0    | 0         |

Nonneurologic controls

|                        | Oxford | Mayo | Euroimmun |
|------------------------|--------|------|-----------|
| HGGN (42)              | 0      | 0    | 0         |

Abbreviations: ADEM = acute disseminated encephalomyelitis; AQP4 = aquaporin-4; CI = confidence interval; CIS = clinically isolated syndrome; HGGN = hypergammaglobulinemia; IDD = inflammatory demyelinating disorder; IgG = immunoglobulin G; LETM = longitudinally extensive transverse myelitis; MOG = myelin oligodendrocyte glycoprotein; MS = multiple sclerosis; NMO = neuromyelitis optica; NPV = negative predictive values; ON = optic neuritis; PPMS = primary progressive multiple sclerosis; PPV = positive predictive values; RIS = radiologically isolated syndrome; RRMS = relapsing remitting multiple sclerosis; SPMS = secondary progressive multiple sclerosis.

* These 2 patients fulfilled McDonald 2017 criteria for MS.
  ** These 2 patients fulfilled McDonald 2017 criteria for MS and Lorscheider et al.10 definition of SPMS.
  ** Patient had primary progressive course with progressive left hemiparesis with spasticity and neurogenic bladder. MRI of the cervical spine showed 2 short-segment T2-hyperintense lesions (left C2-3 and right C6-7).2

neurologic autoimmunity and paraneoplastic disorders; consulted for Grifols, Medimmune, and Euroimmun; and received research support from Grifols, Medimmune, and Alexion. All compensation for consulting activities is paid directly to Mayo Clinic. Go to Neurology.org/N for full disclosures.

Publication history

Received by Neurology May 31, 2018. Accepted in final form November 4, 2018.
A multicenter comparison of MOG-IgG cell-based assays
Patrick J. Waters, Lars Komorowski, Mark Woodhall, et al.
Neurology 2019;92;e1250-e1255 Published Online before print February 6, 2019
DOI 10.1212/WNL.000000000007096

This information is current as of February 6, 2019
| **Updated Information & Services** | including high resolution figures, can be found at: http://n.neurology.org/content/92/11/e1250.full |
|-----------------------------------|--------------------------------------------------------------------------------------------------|
| **Supplementary Material**       | Supplementary material can be found at: http://n.neurology.org/content/suppl/2019/03/12/WNL.0000000000007096.DC1 |
| **References**                   | This article cites 10 articles, 1 of which you can access for free at: http://n.neurology.org/content/92/11/e1250.full#ref-list-1 |
| **Citations**                    | This article has been cited by 8 HighWire-hosted articles: http://n.neurology.org/content/92/11/e1250.full##otherarticles |
| **Subspecialty Collections**     | This article, along with others on similar topics, appears in the following collection(s): All Demyelinating disease (CNS): http://n.neurology.org/cgi/collection/all_demyelinating_disease_cns, All Immunology: http://n.neurology.org/cgi/collection/all_immunology, Autoimmune diseases: http://n.neurology.org/cgi/collection/autoimmune_diseases, Devic's syndrome: http://n.neurology.org/cgi/collection/devics_syndrome, Diagnostic test assessment: http://n.neurology.org/cgi/collection/diagnostic_test_assessment_ |
| **Permissions & Licensing**      | Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://www.neurology.org/about/about_the_journal#permissions |
| **Reprints**                     | Information about ordering reprints can be found online: http://n.neurology.org/subscribers/advertise |